EUVIMEDAtrasti EUVIMED
Crossref

PERSISTENCE OF PH+/CD34+ CELLS IN CHRONIC MYELOID LEUKEMIA PATIENTS IN PROLONGED COMPLETE CYTOGENETIC REMISSION FOLLOWING IMATINIB MESYLATE TREATMENT

M. Defina, M. Bocchia, I. Ippoliti, A. Gozzetti, S. Calabrese, R. Crupi, I. Chitarrelli, F. Lauria

Journal of the Siena Academy of Sciences · 2009

DOI: 10.4081/329 ↗

At a glance

Journal article in Journal of the Siena Academy of Sciences, 2009. Written by M. Defina and 7 co-authors.

SantraukaBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Chronic myelogenous leukemia (CML) is characterized by a clonal expansion of a hematopoietic stem cell possessing a reciprocal translocation between chromosomes 9 and 22, the Philadelphia chromosome, as identified cytogenetically or molecularly (RT-PCR). CML accounts for 15% of adult leukemias. The disease progresses from a chronic phase through an accelerated phase to a blast phase. In the past, the National Comprehensive Cancer Network had suggested that there were three primary treatments available for CML which included: allogeneic bone marrow transplantation (BMT), IFN-α with or without cytarabine, and imatinib mesylate (Glivec®). It has been shown that Glivec is superior to the combination of interferon plus cytarabine. Although BMT can be a curative treatment for CML it is not usually used as a front-line therapy, due to limited donor availability and high toxicity of the procedure. Five-year survival rates following HLA-matched transplants are approximately 75% for patients in chronic phase.

Cite

APA

Defina, M., Bocchia, M., Ippoliti, I., Gozzetti, A., Calabrese, S., Crupi, R., Chitarrelli, I., & Lauria, F. (2009). PERSISTENCE OF PH+/CD34+ CELLS IN CHRONIC MYELOID LEUKEMIA PATIENTS IN PROLONGED COMPLETE CYTOGENETIC REMISSION FOLLOWING IMATINIB MESYLATE TREATMENT. Journal of the Siena Academy of Sciences. https://doi.org/10.4081/329

Vancouver

Defina M, Bocchia M, Ippoliti I, Gozzetti A, Calabrese S, Crupi R, et al. PERSISTENCE OF PH+/CD34+ CELLS IN CHRONIC MYELOID LEUKEMIA PATIENTS IN PROLONGED COMPLETE CYTOGENETIC REMISSION FOLLOWING IMATINIB MESYLATE TREATMENT. Journal of the Siena Academy of Sciences. 2009. doi:10.4081/329

BibTeX
@article{Defina2009,
  author = {Defina, M. and Bocchia, M. and Ippoliti, I. and Gozzetti, A. and Calabrese, S. and Crupi, R. and Chitarrelli, I. and Lauria, F.},
  title = {PERSISTENCE OF PH+/CD34+ CELLS IN CHRONIC MYELOID LEUKEMIA PATIENTS IN PROLONGED COMPLETE CYTOGENETIC REMISSION FOLLOWING IMATINIB MESYLATE TREATMENT},
  journal = {Journal of the Siena Academy of Sciences},
  year = {2009},
  doi = {10.4081/329}
}
Start for free →